Whether or not to administer Amphotericin to an immunosuppressed patient with hematologic malignancy and undiagnosed fever.
D000380:Agranulocytosis / Q000139:chemically induced; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000009:adverse effects; D003630:Daunorubicin / Q000009:adverse effects; D003657:Decision Making; D004941:Esophagitis / Q000188:drug therapy; D005335:Fever of Unknown Origin / Q000188:drug therapy*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*
D003561:Cytarabine; D000666:Amphotericin B; D003630:Daunorubicin